Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Organizing pneumonia secondary to influenza infection: Two case reports and a li...
Información de la revista
Vol. 38. Núm. 3.
Páginas 123-126 (Marzo 2020)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
231
Vol. 38. Núm. 3.
Páginas 123-126 (Marzo 2020)
Brief report
DOI: 10.1016/j.eimc.2019.04.006
Acceso a texto completo
Organizing pneumonia secondary to influenza infection: Two case reports and a literature review
Neumonía organizativa secundaria a infección por el virus de la gripe: comunicación de 2 casos y revisión de la literatura
Visitas
...
Andrea Nuñez-Condea, Ester Marquez-Algabab, Vicenç Falcób, Benito Almiranteb, Joaquin Burgosb,
Autor para correspondencia
jburgos@vhebron.net

Corresponding author.
a Internal Medicine Department, University Hospital Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
b Infectious Diseases Department, University Hospital Vall d’Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (1)
Tablas (1)
Table 1. Basal and clinical characteristics of patients with post-influenza organizing pneumonia.
Abstract
Background

Organizing pneumonia (OP) is a rare complication of influenza virus infection but scarce data are available. The recognition of this entity is important because require appropriate treatment.

Methods

We report two cases and perform a systematic review on PubMed database. Only cases with histological confirmation of OP and influenza virus positive laboratory test were included.

Results

We collected 16 patients. Median age was 52 year, 20% of patients were smokers and 43.8% had not any comorbidity. Influenza A virus infection was diagnosed in 75%. Clinical manifestation consisted on a respiratory deterioration with a median time of appearance of 14 days. Radiological pattern observed was ground-glass opacities with consolidations. Survival was observed in 12 patients (75%). All three patients who did not receive steroid treatment died.

Conclusion

Physicians must be aware that patients with influenza infection with a torpid course could be developing OP and prompt corticoid therapy should be instaured.

Keywords:
Cryptogenic organizing pneumonia
Secondary organizing pneumonia
Bronchiolitis obliterans organizing pneumonia
Influenza virus
Resumen
Antecedentes

La neumonía organizada (OP, por sus siglas en inglés) es una complicación poco frecuente de la gripe. El reconocimiento de esta entidad es importante porque requiere un tratamiento adecuado.

Métodos

Comunicamos 2 casos y realizamos una revisión sistemática en PubMed, incluyendo casos con confirmación histológica de OP y prueba de laboratorio positiva para gripe.

Resultados

Se recogieron 16 pacientes. La edad media fue de 52 años, el 20% eran fumadores y el 43,8% no tenían comorbilidades. El virus de la gripe A se identificó en el 75% de los casos. La presentación clínica consistió en un deterioro respiratorio, con una mediana de aparición de 14 días. El patrón radiológico más común fue opacidades en vidrio esmerilado con consolidaciones. Sobrevivieron 12 pacientes (75%). Los 3 pacientes que no recibieron tratamiento esteroideo murieron.

Conclusión

Los clínicos deben tener en cuenta que los pacientes con gripe con un curso tórpido puedan estar desarrollando una OP.

Palabras clave:
Neumonía organizativa citogenética
Neumonía organizativa secundaria
Bronquiolitis obliterante
Virus de la gripe
Texto completo
Introduction

The influenza virus is a known cause of acute respiratory illness that occurs in epidemics worldwide. The major complications of influenza virus infection (IVI) are secondary bacterial superinfection and viral influenza pneumonia.1 These complications affect especially older patients and those with chronic diseases.2

Organizing pneumonia (OP) is an unusual interstitial lung disease that affects the distal bronchioles and alveoli, it is considered a nonspecific response to a lung injury.3 It can occur associated with connective tissue diseases, drugs, malignancy and bacterial or virus infections.4 Some authors reported that OP might occur as a rare complication after IVI. However, the differential diagnosis between secondary OP and other IVI complications, such as bacterial superinfection, it is difficult. Nevertheless, the diagnosis of secondary OP is important because requires specific therapy.

We report two cases of OP secondary to IVI and, because of the scarce data published about this complication, we carry out a review of published cases in the literature.

Material and methods

We report two cases of secondary OP diagnosed during the influenza outbreak of 2017–2018. A search on PubMed database was conducted to find other reported cases of secondary OP after IVI. The following keywords were used: “cryptogenic organizing-pneumonia”, “secondary organizing-pneumonia”, “bronchiolitis obliterans organizing-pneumonia;” and “influenza virus”. Only cases with histological confirmation of OP and personal history of IVI were included.

ResultsCase 1

A 51-year-old white woman, who was a heavy smoker, was admitted to emergency department complaining of right pleuritic pain, fever, cough and flu-like symptoms. A chest X-ray showed consolidations in lower and medium pulmonary right lobes. Amoxicillin–clavulanic acid was initiated. She was also diagnosed of influenza A and oseltamivir was prescribed. Pneumococcal and Legionella urinary antigen test and blood and sputum culture were negative. Despite treatment, the patient showed a progressive respiratory worsening with new onset left pleuritic pain. At day 12 after admission, a chest computed tomography (CT) revealed consolidations in lower right lobe in resolution, but also appearance of new bilateral consolidations with ground glass opacities in upper pulmonary lobes. Treatment with intravenous methylprednisolone was initiated (dosage 1mg/kg/day). Bronchoscopy was performed, and no virulent pathogens were isolated. Transbronchial biopsy diagnosed OP. Notable clinical improvement after steroid therapy was noticed and the patient was discharged on day 36. After oral prednisone therapy was tapered, disease recurred and she required an increase corticosteroid dosage. After that, the patient evolved correctly.

Case 2

A 55-year-old white male, who was a smoker, with a history of aortic valve replacement, was admitted to hospital with fever, dyspnea, productive cough and flu-like symptoms. Chest X-ray showed bilateral infiltrates. Amoxicillin–clavulanic acid and azithromycin were initiated. The patient presented progressive deterioration with respiratory failure, requiring endotracheal intubation and admission into Intensive Care Unit. He was diagnosed with influenza A infection. Antimicrobial therapy was changed to cefotaxime plus azithromycin plus oseltamivir. No other pathogens were identified. Two weeks later the patient improved and extubation was possible. 27 days after admission, his pulmonary function deteriorated again. Chest-CT showed extensive ground-glass opacities and bilateral consolidations (Fig. 1). Bronchoscopy and transbronchial lung biopsy was performed. All cultures were negative. Treatment with methylprednisolone was initiated (dose 1mg/kg/day) and a progressive improvement was noticed. Histological results of transbronchial biopsy were compatible with OP. The patient was discharged on day 36 and therapy with oral prednisone was tapered. No recurrence of illness was observed.

Fig. 1.

Chest CT of patient 1: (A) day 0: consolidation in lower right lobe; (B) day 12: ground glass opacities plus consolidations in bilateral upper lobes; (C) day 110: almost complete resolution of consolidations.

(0,19MB).
Literature review

We identified a 14 cases of OP secondary to IVI which were reported in 10 publications.4–13 Data is summarized in Table 1.

Table 1.

Basal and clinical characteristics of patients with post-influenza organizing pneumonia.

Author (Ref)  Age  Sex  Smoker  History of lung pathology  Another comorbidities  Initial symptoms  Influenza  UCI  Bacterial infection  Initial treatment  Onset (days)  Radiologic findings  OP symptoms  Histology  Treatment  Outcome 
Fujita J4  38  Female  NS  No  No  Fever, flu symptoms  No  No  ATB+Zanamivir  NS  Bilateral consolidations  No improvement  TB  Steroid pulse  Resolution 
Torrego A5  55  Female  No  Intermittent asthma  No  Myalgia, cough, fever  No  No  ATB+Oseltamivir  30  Bilateral consolidations  Respiratory deterioration (RF)  TB  Steroids 0.75mg/kg  Resolution 
Cornejo R6  52  Female  Yes  No  Osteoarthritis  Cough, fever, myalgia, pleuritic pain, dyspnea  Yes  No  ATB+Oseltamivir+steroids  10  GGO+bilateral consolidations  Respiratory deterioration (RF)  OLB  Steroids 500mg/d 3dtapering 24w  Resolution 
Cornejo R6  36  Male  No  No  Type 2 diabetes  Influenza-like symptoms+dyspnea  Yes  No  ATB+Oseltamivir+steroids  21  GGO+bilateral consolidations  Respiratory deterioration  OLB  Steroids 500mg/d 3dtapering 24w  Resolution 
Marchiori E7  52  Male  No  Yes (not specified)  No  Dyspnea, fever, cough  MV  No  Oseltamivir  15  GGO+bilateral consolidations  Respiratory deterioration  Necropsy  –  Death 
Gómez A8  44  Female  No  No  No  Fever, malaise, headache, myalgias  No  No  Oseltamivir  26  GGO+bilateral consolidation  Respiratory deterioration  TB  Steroids 1mg/kg 4w0.5mg/kg (oral) 6w  Resolution 
Gómez A8  60  Male  No  No  No  Fever, myalgias, arthralgia  No  No  Oseltamivir  21  GGO+bilateral consolidation  Respiratory deterioration  TB  Steroids 1mg/kg 4w0.5mg/kg (oral) 6w  Resolution 
Otto C9  66  Female  No  Usual interstitial pneumonia, double lung transplantation  No  Persistent cough  Yes  No  ATB+Oseltamivir  11  GGO+bilateral consolidations  Respiratory deterioration (RF)  TB  High-dose steroids  Death 
Fujita J10  97  Female  No  No  Type 2 diabetes  Low fever, fatigue  No  No  NS  12  NS  Respiratory deterioration (ARDS)  Necropsy  –  Death 
Fujita J10  37  Male  No  No  Obesity  Fever, productive cough  MV  No  ATB+Oseltamivir  NS  Respiratory deterioration (ARDS)  Necropsy  –  Death 
Kwock W11  45  Female  No  No  No  Fever, dyspnea, productive cough  MV  No  ATB+Oseltamivir  28  GGO+bilateral lung cysts  Respiratory deterioration (RF)  TB  Steroids 0.5mg/kg 8w  Resolution 
Asai N12  23  Female  No  No  No  Fever, sore throat, cough  No  No  ATB+Oseltamivir  GGO+bilateral consolidations  Respiratory deterioration (RF)  TB  Steroids 0.55mg/kg 20w  Resolution 
Anjana V13  60  Female  No  No  No  Fever, chills, bilateral rales  A/B  No  No  NS  14  Bilateral infiltrates  Respiratory deterioration  TB  Steroids  Resolution 
Anjana V13  52  Male  No  No  No  Dyspnea  MV  E. aerogenes  ATB  14  Bilateral infiltrates  Respiratory deterioration (RF)  OLB  Steroids  Resolution 
HUVH  51  Female  Yes  No  Breast cancer  Fever, pleuritic chest pain, cough  No  No  ATB+Oseltamivir  12  GGO+unilateral consolidations  No improvement  TB  Steroids 1mg/g 15dtapering 10w  Resolution 
HUVH  55  Male  Yes  No  Atrial fibrillation, aortic valve replacement  Cough, dyspnea, fever, rhinorrhoea, myalgias  Yes  No  ATB+Oseltamivir  27  GGO+bilateral consolidations  Respiratory deterioration (RF)  TB  Steroids 1mg/kg 6dtapering 12w  Resolution 

ATB: antibiotic treatment; ARDS: acute respiratory distress syndrome; GGO: ground glass opacities; HUVH; Hospital Universitari Vall d’Hebron; MV: mechanical ventilation; NS: not specified; OLB: open lung biopsy; RF: respiratory failure; TB: transbronchial biopsy; w: weeks; d: day.

The median age of patients was 52 years (range 25–97 years) and 62.5% were woman. Only 20% were smokers, 25% had lung disease and 56.3% had any other comorbidity. 43.75% of individuals were previously healthy. Influenza A virus was diagnosed in 75% of cases. Clinical manifestations of secondary OP consisted on a paradoxical respiratory deterioration with cough and dyspnea; 43.8% of them progressed to respiratory failure and 12.5% to acute respiratory distress. The median time of appearance OP symptoms/signs was 14 days (range 7–30 days). The most common radiological pattern observed was bilateral, peripheral, ground-glass opacities with consolidations on chest-CT. Almost all patients (81.3%) received steroid treatment, of those 92.3% survived and 7.7% died. All three patients who did not receive steroid treatment died.

Discussion

Post-influenza OP is a rare complication of IVI that has been described in few case reports.4–13 However, the diagnosis of secondary OP is important, because without appropriate treatment could be fatal. In this article we provide some information that could help clinicians to suspect and diagnose this entity.

The major complication of IVI is bacterial superinfection pneumonia, which occurs most frequently in older patients with underlying chronic diseases.14 Nevertheless, secondary OP affect especially healthy young adults. Cases of post-influenza OP reported in the literature presented with a median age of 50 years, and 50% of them had not any relevant comorbidity.

The time of presentation should be also taking into consideration. Whereas influenza pneumonia is diagnosed in days 4–5 after the first symptoms appear and bacterial superinfection in days 7–10,4,15 in 2/3 of cases reported, secondary OP occurred after two weeks of influenza infection manifestations appears. Moreover, in about a quarter of cases OP occurred later, 4 weeks after the diagnosis of flu.

The typical clinical presentation of OP consists on a subacute paradoxical pulmonary function deterioration with non-productive cough, dyspnea that can progress to respiratory failure and occasionally, fever.

One of the most relevant findings that can lead to the diagnosis of post-influenza OP are the images at the chest-CT. At imaging, the most typical pattern consists on multiple and bilateral ground glass opacities and pulmonary consolidations, with peribronchovascular and subpleural distribution.

Secondary OP remains a diagnosis of exclusion. When the most common diagnoses have been ruled out, more invasive diagnostic procedures should be conducted if the patient's condition allows it. Transbronchial biopsy with anatomopathological examination of the samples obtained gives the definitive diagnosis, although that is only possible in a minority of patients. Histologically, Marchiori et al. correlated pathologic findings with CT images. They found that the areas of consolidation corresponded to alveoli filled with edema fluid, inflammatory exudate or hemorrhage.7 They also found that the ground-glass pattern reflected the alveolar septal thickening. In contrast, lung tissue from individuals affected of IVI showed as predominant features diffuse alveolar damage and alveolar hemorrhage.16

Corticosteroids are the cornerstone in the management of this entity. All post-influenza OP cases were resolved after corticosteroid therapy, except for the patient with personal history of lung transplantation.9 All three patients who did not received corticosteroids died.6,9 In one of the studies found, a patient started steroid therapy after 84 days of initial symptoms and despite improvement, she suffered from secondary extensive lung fibrosis and residual dyspnea.11 So, early corticosteroid treatment should be considered in cases of suspicions OP thus seems to improve outcome and avoid further complications. Most clinicians use moderate doses for prolonged periods of at least 3–6 months, but relapse is common when corticosteroids dosage is tapered off.

In conclusion, physicians must be aware that some patients with IVI, either influenza A or B, and a torpid clinical course could be developing OP. The presentation in healthy young adults 2–4 weeks after the onset of the symptoms, and a new appearance of consolidations or/and ground glass opacities on CT may suggest this diagnosis. In those scenarios, corticoesteroids are the treatment of choice. This entity should be considered in the list of possible complications for patients with influenza who do not improve or have a clinical deterioration.1

Conflict of interest

The authors declare no conflict of interests.

References
[1]
T.M. Uyeki, H.H. Bernstein, J.S. Bradley, J.A. Englund, T.M. File, A.M. Fry, et al.
Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa.
Clin Infect Dis, 68 (2019), pp. e1-e47
[2]
L.A. Grohskopf, L.Z. Sokolow, K.R. Broder, E.B. Walter, A.M. Fry, D.B. Jernigan.
Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices—United States, 2018-19 Influenza Season.
MMWR Recomm Rep, 67 (2018), pp. 1-20
[3]
J.F. Cordier.
Cryptogenic organizing pneumonia.
Eur Respir J, 28 (2006), pp. 422
[4]
J. Fujita, S. Bandoh, M. Yamaguchi, F. Higa, M. Tateyama.
Chest CT findings of influenza virus-associated pneumonia in 12 adult patients.
Influenza Other Respir Viruses, 1 (2007), pp. 183-187
[5]
A. Torrego, V. Pajares, A. Mola, E. Lerma, T. Franquet.
Influenza A (H1N1) organising pneumonia.
BMJ Case Rep, 27 (2010), pp. 2010
[6]
R. Cornejo, O. Llanos, C. Fernández, J. Carlos Díaz, G. Cardemil, J. Salguero, et al.
Organizing pneumonia in patients with severe respiratory failure due to novel A (H1N1) influenza.
BMJ Case Rep, 21 (2010), pp. 2010
[7]
E. Marchiori, G. Zanetti, C.A. Fontes, M.L. Santos, P.M. Valiante, C.M. Mano, et al.
Influenza A (H1N1) virus-associated pneumonia: high-resolution computed tomography–pathologic correlation.
Eur J Radiol, 80 (2011), pp. e500-e504
[8]
A. Gómez-Gómez, R. Martínez-Martínez, M.B. Gotway.
Organizing pneumonia associated with swine-origin influenza A H1N1 2009 viral infection.
AJR Am J Roentgenol, 196 (2011), pp. W103-W104
[9]
C. Otto, D. Huzly, L. Kemna, A. Hüttel, C. Benk, S. Rieg, et al.
Acute fibrinous and organizing pneumonia associated with influenza A/H1N1 pneumonia after lung transplantation.
BMC Pulm Med, 13 (2013), pp. 30
[10]
J. Fujita, Y. Ohtsuki, H. Higa, M. Azuma, T. Yoshinouchi, S. Haranaga, et al.
Clinicopathological findings of four cases of pure influenza virus A pneumonia.
Intern Med, 53 (2014), pp. 1333-1342
[11]
W.C. Kwok, S.H. Lam, M.P. Wong, M.S. Ip, D.C. Lam.
Influenza B/streptococcal co-infection complicated by organizing pneumonia.
Respirol Case Rep, 4 (2016), pp. e00170
[12]
N. Asai, T. Yokoi, N. Nishiyama, Y. Koizumi, D. Sakanashi, H. Kato, et al.
Secondary organizing pneumonia following viral pneumonia caused by severe influenza B: a case report and literature reviews.
BMC Infect Dis, 17 (2017), pp. 572
[14]
M.J. Memoli, R. Athota, S. Reed, L. Czajkowski, T. Bristol, K. Proudfoot, et al.
The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts.
Clin Infect Dis, 58 (2014), pp. 214
[15]
A.M. Ajlan, B. Quiney, S. Nicolaou, N.L. Müller.
Swine-origin influenza A (H1N1) viral infection: radiographic and CT findings.
AJR Am J Roentgenol, 193 (2009), pp. 1494-1499
[16]
T. Mauad, L.A. Hajjar, G.D. Callegari, L.F. da Silva, D. Schout, F.R. Galas, et al.
Lung pathology in fatal novel human influenza A (H1N1) infection.
Am J Respir Crit Care Med, 181 (2010), pp. 72-79
Copyright © 2019. Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica
Opciones de artículo
Herramientas
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

es en pt
Política de cookies Cookies policy Política de cookies
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.